| Literature DB >> 26113652 |
Scott R Evans1, Daniel Rubin2, Dean Follmann3, Gene Pennello4, W Charles Huskins5, John H Powers6, David Schoenfeld7, Christy Chuang-Stein8, Sara E Cosgrove9, Vance G Fowler10, Ebbing Lautenbach11, Henry F Chambers12.
Abstract
Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.Entities:
Keywords: DOOR; RADAR; antibiotic use strategies
Mesh:
Substances:
Year: 2015 PMID: 26113652 PMCID: PMC4542892 DOI: 10.1093/cid/civ495
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079